about
Probing the role of structural features of mouse PrP in yeast by expression as Sup35-PrP fusionsNormal huntingtin function: an alternative approach to Huntington's diseaseDysregulation of upstream binding factor-1 acetylation at K352 is linked to impaired ribosomal DNA transcription in Huntington's disease.Molecular chaperone dysfunction in neurodegenerative diseases and effects of curcumin.Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathwayA cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila.Targeting aggregation in the development of therapeutics for the treatment of Huntington's disease and other polyglutamine repeat diseases.Formation of Hirano bodies induced by expression of an actin cross-linking protein with a gain-of-function mutation.Development of novel therapies for Huntington's disease: hope and challenge.Neurodegenerative disorders: Parkinson's disease and Huntington's diseaseA systematic review of the treatment studies in Huntington's disease since 1990.Modifiers and mechanisms of multi-system polyglutamine neurodegenerative disorders: lessons from fly models.Association of heat-shock proteins in various neurodegenerative disorders: is it a master key to open the therapeutic door?Broad spectrum of hepatocyte inclusions in humans, animals, and experimental models.Cystamine and cysteamine prevent 3-NP-induced mitochondrial depolarization of Huntington's disease knock-in striatal cells.Childhood-onset (Juvenile) Huntington's disease: A rare case report.Antisense RNA sequences modulating the ataxin-1 message: molecular model of gene therapy for spinocerebellar ataxia type 1, a dominant-acting unstable trinucleotide repeat disease.Transforming growth factor-beta1-modulated cerebral gene expression.Glutamine Codon Usage and polyQ Evolution in Primates Depend on the Q Stretch Length.
P2860
Q27022544-C91AF6A7-214E-4C36-8462-FD2960C0B90AQ28281904-F90A8556-A633-4EB8-90FF-545E7F3FD7D0Q34026790-F83642DB-7B06-4E65-AE3C-37C13917D4E2Q34441815-FDA48067-D59B-458B-9917-83090A3D1509Q34923735-44B797F5-7194-4A2F-A710-827B8753F24EQ35022497-D8E03DB7-D6E9-4A7B-89DC-061F61891C7DQ35095142-557A633D-5CB1-4D55-8D77-ADAA6431AFC3Q35613667-2C27DA7F-4D2F-4B79-A7FD-5BAB9BD026AEQ36016932-50A36617-0BB1-4CAA-9007-0FD6528A9108Q36198011-2E72987B-59AA-46CD-A2A3-AA6CB095BE6AQ36719669-C7254BE3-7831-4F6D-A093-E825A09846D3Q37832902-B97CA3C3-699C-4AAF-8545-BF8856B49498Q38149753-E176FAEC-3840-4472-A553-01AFD376EA15Q38165139-30592C5E-139F-450E-88F1-E785CB729080Q40290417-40BE7B19-C405-48E7-8245-30BF71A3071BQ43211838-43CE657E-C953-4BE2-A1FA-98312FFE837AQ45881645-654BC083-3B0E-4028-92EB-21573ACC7A41Q48490693-85BA3DF8-EC15-4CFC-90BD-6E2FE5F4016BQ55042053-0C0AD219-7F5B-479F-AD58-2467DB4D12B3
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Therapeutic opportunities in polyglutamine disease.
@ast
Therapeutic opportunities in polyglutamine disease.
@en
Therapeutic opportunities in polyglutamine disease.
@nl
type
label
Therapeutic opportunities in polyglutamine disease.
@ast
Therapeutic opportunities in polyglutamine disease.
@en
Therapeutic opportunities in polyglutamine disease.
@nl
prefLabel
Therapeutic opportunities in polyglutamine disease.
@ast
Therapeutic opportunities in polyglutamine disease.
@en
Therapeutic opportunities in polyglutamine disease.
@nl
P356
P1433
P1476
Therapeutic opportunities in polyglutamine disease.
@en
P2093
P2888
P304
P356
10.1038/86486
P407
P577
2001-04-01T00:00:00Z